Clinical Trial Update: Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CMD63 CAR T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CMD63 CAR T-cell

Snippet

Sponsor: Chulalongkorn University | Conditions: Relapse B Acute Lymphoblastic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING